specialspack
Bluelighter
I have been think recently about the current situation with regard to the number and variety of "designer" psychoactive agents, which seem to be mostly from the psychedelic group, although there seem to be a few stimulants, dissociatives and possibly opiates around too.
Currently, legislation would seem to be struggling to keep up - with the possible exception of the US (and Australia?) who has an analog law.
In European countries, chemicals are either named speciifically or in "catch-all" groups, like the UK's on phenethylamines.
Recent new compounds are testing the limits of these laws, with methylone, the dragonflys, etc falling outside them.
So how do we think things are going to develop, in these two legislative paradigms? It seems in the UK/European model, there is a limit to the size of group that a catch-all clause delineates - too broad, and it would cover various established medicines, OTC and prescription, which would stir the wrath of the powerful pharmaceutical lobby.
In the US system, this situation is avoided by having the analog laws with its "substantially similar in effects" clause, but eventually it seems that the legislature would be forced into a corner of saying that anything that has broadly defined effects is illegal - seems like we're already halfway to that.
With the current exchange of information on the internet, it takes (relatively) very little time for a drug to be created, for it to by tasted, and to be produced in some form or another by a company or to appear on the streets.
Do you think that the "cat is out of the bag" - that laws are going to struggle to keep up with an ever-expanding field of psychoactives? Or is this wishful thinking - Nicholas Saunders' quote on the back of TIHKAL is of this vein, but now seems somewhat naive (although he was talking more about the extraction of tryptamines from plants).
S.
Currently, legislation would seem to be struggling to keep up - with the possible exception of the US (and Australia?) who has an analog law.
In European countries, chemicals are either named speciifically or in "catch-all" groups, like the UK's on phenethylamines.
Recent new compounds are testing the limits of these laws, with methylone, the dragonflys, etc falling outside them.
So how do we think things are going to develop, in these two legislative paradigms? It seems in the UK/European model, there is a limit to the size of group that a catch-all clause delineates - too broad, and it would cover various established medicines, OTC and prescription, which would stir the wrath of the powerful pharmaceutical lobby.
In the US system, this situation is avoided by having the analog laws with its "substantially similar in effects" clause, but eventually it seems that the legislature would be forced into a corner of saying that anything that has broadly defined effects is illegal - seems like we're already halfway to that.
With the current exchange of information on the internet, it takes (relatively) very little time for a drug to be created, for it to by tasted, and to be produced in some form or another by a company or to appear on the streets.
Do you think that the "cat is out of the bag" - that laws are going to struggle to keep up with an ever-expanding field of psychoactives? Or is this wishful thinking - Nicholas Saunders' quote on the back of TIHKAL is of this vein, but now seems somewhat naive (although he was talking more about the extraction of tryptamines from plants).
S.